{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.17099"}, {"@name": "filename", "#text": "23849_almeida_l_dr_araiq_par.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "RESSALVA \n\nAtendendo solicita\u00e7\u00e3o do(a) \nautor(a), o texto completo deste \n\ntrabalho ser\u00e1 disponibilizado \nsomente a partir de 07/09/2018. \n\n\n\n \nUniversidade Estadual Paulista \n\nInstituto de Qu\u00edmica \n \n \n\n \n\n \n\n \n\nLET\u00cdCIA DE ALMEIDA \n\n \n\n \n\n \n\n \n\nLeishmanioses e derivados de furoxano e benzofuroxano: \n\natividade biol\u00f3gica in vitro e in vivo e potenciais \n\nmecanismos de a\u00e7\u00e3o \n\n \n\n \n\n \n\n \n\nAraraquara \n2017 \n\n  \n\n\n\n \nLET\u00cdCIA DE ALMEIDA \n\n \n \n \n \n\n \n\n \n\nLeishmanioses e derivados de furoxano e benzofuroxano: \n\natividade biol\u00f3gica in vitro e in vivo e potenciais \n\nmecanismos de a\u00e7\u00e3o \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nAraraquara \n2017 \n\n \n\nTese de Doutorado apresentado ao Programa \nde P\u00f3s-Gradua\u00e7\u00e3o em Biotecnologia como \nrequisito parcial para obten\u00e7\u00e3o do t\u00edtulo de \nDoutor pela Universidade Estadual Paulista J\u00falio \nMesquita Filho - UNESP.  \n \nOrientadora: Prof\u00aa. Dr\u00aa. M\u00e1rcia A. S. Graminha. \n\n \n \n\n \n\n\n\nElabora\u00e7\u00e3o:\n\nFICHA CATALOGR\u00c1FICA\n\nSe\u00e7\u00e3o T\u00e9cnica de Aquisi\u00e7\u00e3o e Tratamento da Informa\u00e7\u00e3o\nBiblioteca do Instituto de Qu\u00edmica, Unesp, c\u00e2mpus de Araraquara\n\nA447L\nAlmeida, Let\u00edcia de \n\nLeishmanioses e derivados de furoxano e\nbenzofuroxano: atividade biol\u00f3gica in vitro e in vivo e\npotenciais mecanismos de a\u00e7\u00e3o / Let\u00edcia de Almeida. \u2013\nAraraquara : [s.n.], 2017\n\n130 f. : il.\n\nTese (doutorado) \u2013 Universidade Estadual Paulista,\nInstituto de Qu\u00edmica\n\nOrientador: M\u00e1rcia Aparecida Silva Graminha\n\n1. Leishmania. 2. Leishmaniose. 3. Compostos bioativos.\n4. Proteinase. 5. C\u00e1lcio-Metabolismo. I. T\u00edtulo.\n\n\n\n2 \n\n \n\n \n\n \n\n\n\n3 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\u201cO talento vence jogos, mas s\u00f3 o trabalho em equipe ganha campeonatos\u201d. \n\n \n\nMichael Jordan \n\n \n\n\n\n4 \n\n \n\nAGRADECIMENTOS \n\n \n\n\u00c0 Deus por ser a for\u00e7a condutora de minha vida, por espalhar luz em mim e nos que me cercam, \n\npor me fortalecer nos momentos de dificuldade e por ter tra\u00e7ado a mim caminhos que fizeram \n\nchegar at\u00e9 aqui; \n\n \n\n\u00c0 minha fam\u00edlia, em especial aos meus pais Neusa e Jos\u00e9 Antonio e irm\u00e3o Jos\u00e9 Ricardo que \n\nsempre me dedicaram muito amor e apoio constante; \n\n \n\nAo meu namorado Rafael Marangoni que esteve sempre presente e apoiando-me; \n\n \n\n\u00c0 Prof\u00aa. Dr\u00aa. Marcia Graminha pela orienta\u00e7\u00e3o, pela oportunidade e confian\u00e7a depositada, e por \n\nme encorajar nas apresenta\u00e7\u00f5es ao longo do doutorado; \n\n \n\nAos amigos do Laborat\u00f3rio de Bioqu\u00edmica e Biologia Molecular de Tripanosomat\u00eddeos-UNESP, \n\nTha\u00eds, F\u00e1bio, Mayara, Camila, Amanda, Leandro, Rhayanne, Kely, J\u00e9ssica, Alex e Angela pelos \n\naprendizados durante esses anos de conv\u00edvio; \n\n \n\nA todos do Laborat\u00f3rio de Parasitologia B\u00e1sica, em especial o Prof. Dr. Jo\u00e3o Aristeu da Rosa, \n\nProf\u00aa Dr\u00aa Mara Cristina Pinto e a aluna Aline Rimoldi que nos acolheram em seu laborat\u00f3rio \n\nenquanto o pr\u00e9dio do DAC ainda estava em constru\u00e7\u00e3o; \n\n \n\n\u00c0 Isabel Martinez, quem se disp\u00f4s a me ouvir e me aconselhar quando precisei e quem tamb\u00e9m \n\nme ajudou em diversos experimentos, mesmo aqueles em pleno carnaval; \n\n \n\nAo Prof. Dr. Jean Leandro dos Santos e os alunos Luiz Antonio Dutra e Aline Pavan pela \n\ncolabora\u00e7\u00e3o, momentos de discuss\u00e3o de resultados e por cederem as mol\u00e9culas que foram \n\ntestadas; \n\n \n\nAo Prof. Dr. Cleverton Roberto de Andrade pela colabora\u00e7\u00e3o e apoio nos ensaios \n\nhistopatol\u00f3gicos e ainda pelos ensinamentos e conselhos dados; \n\n\n\n5 \n\n \n\n \n\nAo Prof. Dr. Jeremy Mottram e Prof. Dr. Graham Coombs e os alunos Elmarie Myburgh e \n\nGareth Westrop que me ajudaram nos ensaios com ciste\u00edno proteases e possibilitaram discuss\u00f5es \n\nimportantes para o trabalho;  \n\n \n\nA todos da Universidade de Glasgow que me receberam, em especial a Amy, Andrea e Kirsten as \n\nquais me acolheram com mais amizade; \n\n \n\n\u00c0 Prof\u00aa Dr\u00aa Angela Kaysel Cruz e aluna Eliza Vanessa C. A. Ferreira que nos nortearam para os \n\nensaios in vivo;  \n\n \n\nAos amigos Tha\u00eds, Amanda, Leandro, Rhayanne, Aline, Mayara e F\u00e1bio os quais a amizade e o \n\ncompanheirismo se estenderam al\u00e9m do conv\u00edvio do laborat\u00f3rio; \n\n \n\nA FAPESP e CNPq (processo: 140452/2013-3) pelo apoio financeiro e pela bolsa concedida; \n\n \n\nA todos que direta ou indiretamente me apoiaram para a conclus\u00e3o de mais uma etapa de minha \n\nvida. Obrigada! \n\n  \n\n\n\n6 \n\n \n\n \n\nRESUMO \n\n \n\nAs leishmanioses s\u00e3o doen\u00e7as causadas pelo protozo\u00e1rio parasito do g\u00eanero Leishmania \ne transmitidas pela picada do insetor vetor, o flebotom\u00edneo. As leishmanioses apresentam \ndiferentes manifesta\u00e7\u00f5es cl\u00ednicas, sendo elas leishmaniose cut\u00e2nea, mucocut\u00e2nea, \ncut\u00e2nea difusa e visceral. Os f\u00e1rmacos atualmente dispon\u00edveis para o tratamento das \nleishmanioses apresentam diversos efeitos colaterais, al\u00e9m de problemas associados \u00e0s \nvias de administra\u00e7\u00e3o e surgimento de cepas resistentes. Os furoxanos e benzofuroxanos \ns\u00e3o compostos heteroc\u00edclicos contendo a fun\u00e7\u00e3o N-\u00f3xido com m\u00faltiplas atividades, \nincluindo anti-T. cruzi e anti-Leishmania. Neste trabalho, uma s\u00e9rie de derivados de \nfuroxano (compostos 3, 4a-b, 13a-b, e 14a-f) e benzofuroxano (7 e 8a-c) foram avaliados \nem ensaios in vitro frente as esp\u00e9cies L. (L.) amazonensis, L. (L.) mexicana e L. (L.) \ninfantum. Os compostos foram tamb\u00e9m avaliados quanto \u00e0 citotoxicidade em macr\u00f3fagos \nmurinos e quanto \u00e0 sua capacidade de produ\u00e7\u00e3o de \u00f3xido n\u00edtrico in vitro e em macr\u00f3fagos \ninfectados com o parasito. A atividade leishmanicida (EC50) dos derivados em estudo \nvariou de 2,0 a 96,0 \u00b5M, enquanto que a citotoxicidade de 5,0 a 250,0 \u00b5M. A mol\u00e9cula \ndoadora de \u00f3xido n\u00edtrico 14e revelou ser a mais promissora dentre os derivados \nanalisados, exibindo a\u00e7\u00e3o pH-dependente. Adicionalmente, o derivado 14e mostrou ser \ncapaz de inibir a enzima ciste\u00edno protease de Leishmania, importante fator de virul\u00eancia \ndeste parasito. Estes ensaios mostraram que 14e inibe a isoforma recombinante de \nciste\u00edno protease B 2.8 (IC50 = 1,0 \u00b5M), com poss\u00edvel envolvimento da ciste\u00edno protease \nA no mecanismo de a\u00e7\u00e3o desse derivado, como revelado em ensaios realizados com \nlinhagens nocautes de L. (L.) mexicana para os genes codificadores destas enzimas. \nEstudos de biologia celular realizados indicaram ainda poss\u00edvel intera\u00e7\u00e3o do 14e com \noutros alvos de a\u00e7\u00e3o, como altera\u00e7\u00f5es na homeostase do c\u00e1lcio. Nos estudos in vivo \nrealizados com hamsters infectados com L. (L.) infantum constatou-se que o tratamento \ncom uma dose de 3,0 mg/Kg/dia do 14e levou a uma redu\u00e7\u00e3o significativa da carga \nparasit\u00e1ria no ba\u00e7o (49,9%) e no f\u00edgado (54,2%) tamb\u00e9m n\u00e3o se verificou efeitos t\u00f3xicos \npelas an\u00e1lises bioqu\u00edmicas e histopatol\u00f3gicas conduzidas. Desta forma, este trabalho \nindica o derivado furoxano 14e como uma mol\u00e9cula promissora para o desenvolvimento \nde um agente leishmanicida.  \n \n\nPalavras-chave: Leishmania. Atividade leishmanicida in vitro e in vivo. Furoxanos. \n\nBenzofuroxanos. Ciste\u00edno proteases. Homeostase de c\u00e1lcio.  \n\n\n\n7 \n\n \n\nABSTRACT \n\n \n\nLeishmaniases are diseases caused by the protozoan parasite of Leishmania genus and \ntransmitted by the bite of insect vetor, phlebotomine. Leishmaniases present different \nclinical manifestations, including cutaneous, mucocutaneous, diffuse cutaneous and \nvisceral leishmaniasis. The currently available drugs for leishmaniasis treatment show \nseveral side effects, besides problems associated with the administration routes and the \nemergence of resistant strains. Furoxan and benzofuroxan are heterocyclic compounds \ncontaining the N-oxide function showing several activities, including anti-T. cruzi and anti-\nLeishmania. In this work, a series of furoxan (compounds 3, 4a-b, 13a-b, and 14a-f) and \nbenzofuroxan (7 and 8a-c) derivatives were tested against the species L. (L.) \namazonensis, L. (L.) mexicana e L. (L.) infantum. The compounds were also evaluated \nfor cytotoxicity against murine macrophages and as to its ability to produce nitric oxide in \nvitro and in macrophages infected with the parasite. The antileishmanial activity (EC50) of \nthe derivatives studied ranged from 2.0 to 96.0 ?M, whereas the cytotoxicity of 5.0 to 250.0 \n?M. The nitric oxide donor molecule 14e revealed to be the most promising of the analyzed \nderivatives, exhibiting a pH-dependent action. Futhermore, the derivative 14e was shown \nto be capable of inhibiting the cysteine protease enzyme of Leishmania, an important \nvirulence factor of this parasite. These assays showed that 14e inhibits the cysteine \nprotease B 2.8 recombinant isoform (IC50 = 1.0 ?M), with possible involvement of the \ncysteine protease A in the mechanism of action of this derivative, as revealed in tests \nperformed with knockouts L. (L.) mexicana mutants for the genes encoding these \nenzymes. Cell biology studies have also indicated possible interaction of 14e with other \naction targets, such as changes in calcium homeostasis. In the in vivo studies using L. \ninfantum-infected hamsters it was found that the treatment with a dose of 3.0 mg/Kg/day \nof 14e led to a meaningful reduction of parasite load in spleen (49.9%) and liver (54.2%), \nmoreover no toxic effects were detected by the biochemical and histopathological \nanalyzes conducted. Thus, this work indicates the furoxan derivative 14e as a promising \nmolecule for the development of an antileishmanial agent. \n \n\nKeywords: Leishmania. In vitro and in vivo antileishmanial activity. Furoxans. \n\nBenzofuroxans. Cisteine proteases. Calcium homeostasis.  \n\n  \n\n\n\n8 \n\n \n\nLISTA DE ABREVIATURAS, SIGLAS E \n\nS\u00cdMBOLOS \n\nALT............Alanina aminotransferase \n\nALP............Fosfatase alcalina \n\nAnfB ..........Anfotericina B \n\nARG\u2026\u2026\u2026Arginase \n\nARG1.........Via da Arginase \n\nAST............Aspartato aminotransferase \n\nATP............Adenosina Trifosfato \n\nCC50............Concentra\u00e7\u00e3o Citot\u00f3xica para 50% da \n\npopula\u00e7\u00e3o \n\nCP\u2026\u2026\u2026\u2026.Ciste\u00edna Protease \n\nCPA\u2026\u2026\u2026..Ciste\u00edna Protease tipo A \n\nCPB\u2026\u2026\u2026..Ciste\u00edna Protease tipo B \n\nCPC\u2026\u2026\u2026..Ciste\u00edna Protease tipo C \n\nDMSO.........Dimetilsulf\u00f3xido \n\nDN...............Doen\u00e7a Negligenciada \n\nDNDi...........Iniciativa de F\u00e1rmacos para Doen\u00e7as \n\nNegligenciadas  \n\nEC50-AMA......Concentra\u00e7\u00e3o Efetiva para 50% de \n\nformas amastigotas \n\nEC50-PRO......Concentra\u00e7\u00e3o Efetiva para 50% de \n\nformas promastigotas \n\nEROs..........Esp\u00e9cies Reativas de Oxig\u00eanio \n\nFc?Rs.........Receptores Gama Fc \n\nFDA............Administra\u00e7\u00e3o de F\u00e1rmacos e \n\nAlimentos  \n\nGP63..........Metaloprotease de Superf\u00edcie \n\nH&amp;E............Hematoxilina/Eosina \n\nHPLC............Cromatografia L\u00edquida de Alta \n\nPerformance \n\ni.p..................Via Intraperitoneal \n\nIC50................Concentra\u00e7\u00e3o Efetiva para Inibi\u00e7\u00e3o \n\n50% de Enzima \n\nIFN-?..............Interferon ? \n\nIgE.................Imunoglobulina E \n\nIgG................Imunoglobulina G \n\nIgM................Imunoglobulina M \n\nIV...................\u00cdndice de Varia\u00e7\u00e3o \n\nIS...................\u00cdndice de seletividade \n\nL-Arg.............L-arginina \n\nLaWT............L. (L.) amazonensis sens\u00edvel ao 14e \n\n \n\nLa14eR.........L. (L.) amazonensis cultivada na \n\npresen\u00e7a do 14e \n\nLC.................Leishmaniose Cut\u00e2nea \n\nLCD..............Leishmaniose Cut\u00e2nea Difusa \n\nLDPC............Leishmaniose Dermal P\u00f3s-Calazar \n\nLiWT.............L. (L.) infantum sens\u00edvel ao 14e \n\nLi14eR..........L. (L.) infantum cultivada na presen\u00e7a \n\ndo 14e \n\nLM.................Leishmaniose Mucocut\u00e2nea \n\nLPG...............Lipofosfoglicanos \n\nLPS...............Lipopolissacar\u00eddeo \n\nLV..................Leishmaniose Visceral \n\nMHC II...........Complexo de Histocompatibilidade II \n\nMTT...............Brometo de 3-[4,5-dimetiltiazol-2-il]-\n\n2,5-difenil tetraz\u00f3lio \n\nnm.................nan\u00f4metros  \n\nNO.................\u00d3xido N\u00edtrico \n\nNOS2............\u00d3xido N\u00edtrico Sintase 2 \n\nOMS.............Organiza\u00e7\u00e3o Mundial de Sa\u00fade \n\nPMS..............Metosulfato de fenazina \n\nrCPB2.8........Isoforma Recombinante da CPB 2.8 \n\nde L. (L.) mexicana  \n\nRPMI............Meio Roswell Park Memorial Institute \n\nSbIII................Antimonial Trivalente \n\nSbV................Antimonal Pentavalente \n\nSDS...............Duodecil Sulfato de S\u00f3dio \n\nTh1................C\u00e9lula T helper tipo 1 \n\nTh2................C\u00e9lula T helper tipo 2 \n\nTGF-?............Fator de Transforma\u00e7\u00e3o do \n\nCrescimento ? \n\nTNF-?............Fator de Necrose Tumoral ? \n\nZ-FR-pNA.......Z-Phe-Arg-p-Nitroanilida \n\nZM..................Zona Marginal \n\n?.....................Comprimento de onda \n\n??m...............Potencial de Membrana Mitocondrial \n\n?cpb...............Mutantes Nulos para cpb \n\n?cpa/?cpb......Mutantes Nulos para cpa e cpb \n\n?cpb+pXcpb2.8.....Mutantes Nulos para cpb e \n\nsuprerexpressora da rCPB2.8 \n\n?F...................Fluoresc\u00eancia Relativa \n\n\n\n9 \n \n\nLISTA DE FIGURAS \n\n \n\nFigura 1. Distribui\u00e7\u00e3o mundial das leishmanioses em 2013...........................................18 \n \nFigura 2. Observa\u00e7\u00e3o microsc\u00f3pica de protozo\u00e1rios do g\u00eanero Leishmania.................20 \n \nFigura 3. Ciclo da vida do protozo\u00e1rio Leishmania.........................................................22 \n \nFigura 4. Manifesta\u00e7\u00f5es cl\u00ednicas da leishmaniose tegumentar.......................................24 \n \nFigura 5. Manifesta\u00e7\u00f5es cl\u00ednicas da leishmaniose visceral.............................................25 \n \nFigura 6. Mapa de distribui\u00e7\u00e3o dos casos de leishmanioses e casos de coinfec\u00e7\u00e3o \nLeishmania/HIV no mundo at\u00e9 2001................................................................................26 \n \nFigura 7. Estruturas qu\u00edmicas dos f\u00e1rmacos utilizados no tratamento das \nleishmanioses..................................................................................................................29 \n \nFigura 8. Projetos do DNDi..............................................................................................35 \n \nFigura 9. Cl\u00e3s e fam\u00edlias de proteases de L. (L.) major. A nomenclatura \u00e9 baseada no \nbanco de dados MEROPS (http://merops.sanger.ac.uk/)...............................................39 \n \nFigura 10. Representa\u00e7\u00e3o diagram\u00e1tica de intera\u00e7\u00e3o do substrato pept\u00eddico com os \nbols\u00f5es de s\u00edtio ativo de uma ciste\u00edno protease..............................................................40 \n \nFigura 11. Via L-Arg e determina\u00e7\u00e3o do resultado da infec\u00e7\u00e3o......................................42 \n \nFigura 12. Transporte, bioss\u00edntese, interconvers\u00e3o e utiliza\u00e7\u00e3o das poliaminas em \nLeishmania e via da tripanotiona.....................................................................................44 \n \nFigura 13. Representa\u00e7\u00e3o esquem\u00e1tica da via de ativa\u00e7\u00e3o de macr\u00f3fagos e resultado \nda infec\u00e7\u00e3o......................................................................................................................45 \n \nFigura 14. Estrutura qu\u00edmica dos derivados furox\u00e2nicos (4a, 4b, 14a-f) e \nbenzofurox\u00e2nicos (8a-c) e os compostos precursores (3, 7, 13a e \n13b).................................................................................................................................48 \n \nFigura 15. Representa\u00e7\u00e3o esquem\u00e1tica da disposi\u00e7\u00e3o dos compostos e parasitos em \nplacas de 96 po\u00e7os do ensaio com formas promastigotas de Leishmania.....................56 \n \nFigura 16. Concentra\u00e7\u00e3o de NO em mM produzido por macr\u00f3fagos infectados com L. \n(L.) amazonensis na presen\u00e7a de derivados furoxanos ou benzofuroxanos..................77 \n \nFigura 17. Concentra\u00e7\u00e3o de NO em \u00b5M produzido por macr\u00f3fagos infectados com L. \n(L.) infantum na presen\u00e7a de derivados furoxanos ou benzofuroxanos.........................78 \n\n\n\n10 \n \n\n \nFigura 18. Ensaio de estabilidade in vitro de 14a (A) e 14e (B) nos pHs 5,4 e 7,0.........80 \n \nFigura 19. A\u00e7\u00e3o pH-dependente dos derivados furox\u00e2nicos 14a e 14e em macr\u00f3fagos \ninfectados com amastigotas de Leishmania....................................................................82 \n \nFigura 20. Estrutura qu\u00edmica do derivado furox\u00e2nico 14e, evidenciando N-acil hidrazona \ne ataque nucleof\u00edlico de um res\u00edduo de amino\u00e1cido 14e................................................83 \n \nFigura 21. Ensaio de mecanismo de inibi\u00e7\u00e3o da rCPB2.8 pelo derivado 14e................87 \n \nFigura 22. Curva de crescimento das linhagens selvagem e resistente de L. (L.) \namazonensis e L. (L.) infantum em meio de cultura........................................................90 \n \nFigura 23. Ensaio de mobiliza\u00e7\u00e3o de c\u00e1lcio intracelular.................................................92 \n \nFigura 24. Tratamento de hamsters infectados com L. (L.) infantum com 14e ou  \nAnfB................................................................................................................................95 \n \nFigura 25. Avalia\u00e7\u00e3o da toxicidade em hamsters infectados com L. (L.) infantum ap\u00f3s \ntratamento com 14e ou AnfB..........................................................................................99 \n \nFigura 26. Estrutura geral do f\u00edgado..............................................................................101 \n \nFigura 27. Altera\u00e7\u00f5es histopatol\u00f3gicas no f\u00edgado de hamster infectado com L. (L.) \ninfantum ap\u00f3s tratamento com 14e ou AnfB durante 15 dias.......................................103 \n \nFigura 28. Fotomicrografia das altera\u00e7\u00f5es histopatol\u00f3gicas do f\u00edgado de hamster \ninfectado com L. (L.) infantum tratamento com 14e ou AnfB durante 15 dias..............104 \n \nFigura 29. Fotomicrografia das altera\u00e7\u00f5es histopatol\u00f3gicas no f\u00edgado e ba\u00e7o de hamster \ninfectado com L. (L.) infantum ap\u00f3s tratamento com 14e ou AnfB durante 15 dias.....105 \n \nFigura 30. Estrutura geral do ba\u00e7o................................................................................106 \n \n\nFigura 31. Fotomicrografia das altera\u00e7\u00f5es histopatol\u00f3gicas no ba\u00e7o de hamster \ninfectado com L. (L.) infantum ap\u00f3s tratamento com 14e ou AnfB durante 15 dias.....108 \n \nFigura 32. Estrutura geral do rim...................................................................................109 \n \nFigura 33. Fotomicrografia das altera\u00e7\u00f5es histopatol\u00f3gicas no rim de hamster infectado \ncom L. (L.) infantum ap\u00f3s tratamento com 14e ou AnfB durante 15 dias.....................111 \n \nFigura 34. Hip\u00f3tese do mecanismo de a\u00e7\u00e3o do derivado furox\u00e2nico 14e....................112 \n  \n\n\n\n11 \n \n\nLISTA DE QUADROS E TABELAS \n\nQuadro 1. F\u00e1rmacos utilizados no tratamento das leishmanioses, propriedades, \nadministra\u00e7\u00e3o e coment\u00e1rios...........................................................................................28 \n \nTabela 1. Derivados furox\u00e2nicos e benzofurox\u00e2nicos, c\u00f3digo e estrutura qu\u00edmica...........52 \n \nTabela 2. Determina\u00e7\u00e3o da concentra\u00e7\u00e3o efetiva em formas promastigotas (EC50-PRO, \u00b5M) \nde L. (L.) amazonensis e L. (L.) infantum, e citotoxicidade (CC50, \u00b5M) em macr\u00f3fagos \nperitoneais murinos dos derivados de furoxano, benzofuroxano e seus \nprecursores......................................................................................................................69  \n \n\nTabela 3. Determina\u00e7\u00e3o da concentra\u00e7\u00e3o efetiva em formas amastigotas (EC50-AMA, \u00b5M) \nde L. (L.) amazonensis e L. (L.) infantum, e citotoxicidade (CC50, \u00b5M) em macr\u00f3fagos \nperitoneais murinos dos derivados de furoxano e \nbenzofuroxano.................................................................................................................73 \n \n\nTabela 4. Libera\u00e7\u00e3o de NO in vitro (%). Cada valor corresponde \u00e0 m\u00e9dia de tr\u00eas \nexperimentos realizados em triplicatas \u00b1 desvio padr\u00e3o..................................................75 \n \nTabela 5. Determina\u00e7\u00e3o da concentra\u00e7\u00e3o efetiva em formas promastigotas (EC50-PRO, \u00b5M) \ne amastigotas (EC50-AMA, \u00b5M) e atividade inibit\u00f3ria de isoforma recombinante de rCPB2.8 \n(IC50, \u00b5M) de L. (L.) mexicana dos derivados de furoxano e \nbenzofuroxano.................................................................................................................85 \n \nTabela 6. Determina\u00e7\u00e3o da concentra\u00e7\u00e3o efetiva, pelo derivado furox\u00e2nico 14e, em \nformas amastigotas (EC50-AMA, \u00b5M) de L. (L.) mexicana em diferentes linhagens: \nselvagem, mutante nocaute para CPB (?cpb), mutante duplo nocaute para CPB e CPA \n(?cpa/?cpb) e mutante nocaute para CPB e superexpressor de CPB 2.8 \n(?cpb+pXcpb2.8) (EC50-AMA)............................................................................................88 \n \nTabela 7. Valores de EC50-PRO das linhagens selvagem e resistente de L. (L.) \namazonensis e L. (L.) infantum frente ao composto 14e..................................................89 \n \n \n \n \n\n  \n\n\n\n12 \n \n\nSum\u00e1rio \n\n1 INTRODU\u00c7\u00c3O ............................................................................................................ 15 \n\n2 REVIS\u00c3O DE LITERATURA ...................................................................................... 17 \n\n2.1 Doen\u00e7as Negligenciadas ....................................................................................... 17 \n\n2.2 Leishmanioses ....................................................................................................... 19 \n\n2.3 Manifesta\u00e7\u00f5es Cl\u00ednicas .......................................................................................... 23 \n\n2.4 Tratamento Farmacol\u00f3gico ................................................................................... 27 \n\n2.4.1 Tratamento de primeira escolha ............................................................................ 29 \n\n2.4.2. Tratamento de segunda escolha .......................................................................... 31 \n\n2.4.3. Novos f\u00e1rmacos e o pipeline do DNDi .................................................................. 34 \n\n2.5 Derivados de Furoxano e Benzofuroxano ............................................................ 36 \n\n2.6 Ciste\u00edno Proteases ................................................................................................. 37 \n\n2.7 Leishmania e o Escape do Sistema Imune do Hospedeiro ................................ 41 \n\n2.8 Resposta Imune \u00e0 Doen\u00e7a ..................................................................................... 44 \n\n2.9 C\u00e1lcio, Mitoc\u00f4ndria e EROs ................................................................................... 46 \n\n3 OBJETIVOS ................................................................................................................ 49 \n\n3.1 Objetivos Gerais ..................................................................................................... 49 \n\n3.2 Objetivos Espec\u00edficos ............................................................................................ 49 \n\n3.2.1 Avalia\u00e7\u00e3o da atividade in vitro anti-Leishmania ..................................................... 49 \n\n3.2.2 Estudos de Mecanismos de a\u00e7\u00e3o .......................................................................... 50 \n\n3.2.3 Avalia\u00e7\u00e3o da efic\u00e1cia in vivo do derivado 14e em modelo de LV .......................... 50 \n\n4 MATERIAL E M\u00c9TODOS ........................................................................................... 51 \n\n4.1 Reagentes ............................................................................................................... 51 \n\n4.2 Parasitos e C\u00e9lulas de Mam\u00edferos ........................................................................ 54 \n\n4.3 Animais para Experimenta\u00e7\u00e3o .............................................................................. 55 \n\n4.4 Ensaios de atividade leishmanicida in vitro ........................................................ 55 \n\n4.4.1 Bioensaio para avaliar a atividade leishmanicida in vitro em formas promastigotas \n\nde L. (L.) amazonensis e L. (L.) infantum ....................................................................... 55 \n\n4.4.2 Bioensaio para determinar a citotoxicidade in vitro em macr\u00f3fagos peritoneais \n\nmurinos .......................................................................................................................... 57 \n\n4.4.3 Bioensaio para avaliar a atividade leishmanicida in vitro em formas amastigotas \n\nintracelulares de L. (L.) amazonensis e L. (L.) infantum ................................................. 58 \n\n\n\n13 \n \n\n4.4.4 Dosagem de \u00f3xido n\u00edtrico in vitro .......................................................................... 58 \n\n4.4.5 Dosagem de \u00f3xido n\u00edtrico em sobrenadante de cultura de c\u00e9lulas ....................... 59 \n\n4.5 Ensaio de Estabilidade dos Derivados Furox\u00e2nicos e Benzofurox\u00e2nicos ........ 60 \n\n4.6 Ensaios de inibi\u00e7\u00e3o da enzima Ciste\u00edno Protease de L. (L.) mexicana ............. 60 \n\n4.6.1 Bioensaio para avaliar a atividade leishmanicida in vitro em formas promastigotas \n\nde L. (L.) mexicana ......................................................................................................... 60 \n\n4.6.2 Bioensaio para avaliar a atividade leishmanicida in vitro em formas amastigotas \n\nintracelulares de L. (L.) mexicana .................................................................................. 61 \n\n4.6.3 Ensaio para avaliar a atividade inibit\u00f3ria de ciste\u00edno protease (rCPB 2.8) de L. (L.) \n\nmexicana por compostos derivados de furoxano e benzofuroxano ................................ 61 \n\n4.6.4 Bioensaio para avaliar a atividade leishmanicida do derivado 14e em diferentes \n\nlinhagens de L. (L.) mexicana ........................................................................................ 62 \n\n4.7 Ensaios com Leishmania para Desenvolvimento de Cepa Resistente ao \n\nDerivado 14e ................................................................................................................. 63 \n\n4.7.1 Desenvolvimento da cepa de Leishmania resistente ao derivado 14e .................. 63 \n\n4.8 Ensaios para Avaliar a Homeostase do C\u00e1lcio .................................................... 64 \n\n4.8.1 Marca\u00e7\u00e3o de promastigotas de L. (L.) amazonensis com Fluo8-AM ..................... 64 \n\n4.8.2 Avalia\u00e7\u00e3o dos n\u00edveis de c\u00e1lcio em promastigotas de L. (L.) amazonensis ............ 64 \n\n4.9 Ensaios in vivo ....................................................................................................... 65 \n\n4.9.1 Bioensaio para avaliar a efic\u00e1cia do composto 14e no tratamento da LV ............. 65 \n\n4.9.2 Avali\u00e7\u00e3o da carga parasit\u00e1ria por dilui\u00e7\u00e3o limitante ............................................... 66 \n\n4.9.3 Avali\u00e7\u00e3o toxicol\u00f3gica ............................................................................................. 66 \n\n4.9.4 Avali\u00e7\u00e3o histopatol\u00f3gica ........................................................................................ 66 \n\n5 RESULTADOS E DISCUSS\u00c3O .................................................................................. 68 \n\n5.1 O Derivado Furox\u00e2nico 14e Apresentou Atividade Leishmanicida nos Ensaios \n\nin vitro ........................................................................................................................... 68 \n\n5.1.1 Ensaios de atividade antipromastigota para L. (L.) amazonensis indicam os \n\nderivados 8a, 14a, 14b, 14c, 14d e 14e para avalia\u00e7\u00e3o antiamastigota ........................ 70 \n\n5.1.2 Ensaios de atividade antipromastigota para L. (L.) infantum indicam os derivados \n\n4a, 8a, 8b, 8c, 14b, 14c, 14d e 14e para avalia\u00e7\u00e3o antiamastigota ............................... 71 \n\n5.1.3 Ensaios de atividade antiamastigota para L. (L.) amazonensis e L. (L.) infantum \n\nindicam os derivados 14b, 14d e 14e como promissores candidatos no tratamento da \n\nLC ou LV ........................................................................................................................ 72 \n\n\n\n14 \n \n\n5.1.4 Ensaios de dosagem de \u00f3xido n\u00edtrico indicam 14e como liberador de NO in vitro e \n\nem macr\u00f3fagos infectados com L. (L.) amazonensis ou L. (L.) infantum ....................... 73 \n\n5.1.5 A estabilidade dos derivados de furoxanos indicam uma atividade pH-dependente \n\nda mol\u00e9cula .................................................................................................................... 79 \n\n5.1.6 Alguns derivados furox\u00e2nicos s\u00e3o inibidores de CP e exibem atividade \n\nleishmanicida em L. (L.) mexicana ................................................................................. 83 \n\n5.1.7 O composto 14e \u00e9 um inibidor n\u00e3o-competitivo .................................................... 86 \n\n5.1.8 O composto 14e pode apresentar outros alvos de a\u00e7\u00e3o em Leishmania .............. 87 \n\n5.1.9 Ensaios iniciais indicam outros poss\u00edveis alvos de a\u00e7\u00e3o em Leishmania do \n\nderivado 14e: altera\u00e7\u00f5es nos n\u00edveis de c\u00e1lcio intracelular ............................................. 92 \n\n5.2 Ensaios in vivo ....................................................................................................... 93 \n\n5.2.1 O derivado 14e reduziu a carga parasit\u00e1ria in vivo no f\u00edgado e ba\u00e7o na dose de \n\n3,0 mg/Kg/dia ................................................................................................................. 93 \n\n5.2.2 O tratamento com 14e na dose de 3,0 mg/Kg/dia n\u00e3o exibiu toxicidade de acordo \n\ncom os marcadores bioqu\u00edmicos de toxicidade .............................................................. 96 \n\n5.2.3 O tratamento com 14e na dose de 3,0 mg/Kg/dia n\u00e3o causou efeitos t\u00f3xicos no \n\nf\u00edgado, ba\u00e7o e rim pelas an\u00e1lises histopatol\u00f3gicas ...................................................... 100 \n\n7 CONCLUS\u00d5ES ......................................................................................................... 113 \n\nREFER\u00caNCIAS ............................................................................................................ 115 \n\n \n\n \n\n \n\n  \n\n\n\n15 \n \n\n1 INTRODU\u00c7\u00c3O  \n\n \n\nAs leishmanioses est\u00e3o presentes em 98 pa\u00edses, com cerca de 12 milh\u00f5es de \n\npessoas infectadas no mundo (McGWIRE; SATOSKAR, 2014; WHO, 2010). A doen\u00e7a \n\napresenta diferentes manifesta\u00e7\u00f5es cl\u00ednicas, sendo elas leishmaniose cut\u00e2nea (LC), \n\nleishmaniose mucocut\u00e2nea (LM), leishmaniose cut\u00e2nea difusa (LCD) e leishmaniose \n\nvisceral (LV) (BARRETT; CROFT, 2012). Cerca de vinte esp\u00e9cies de Leishmania s\u00e3o \n\nconhecidas como os agentes causadores de leishmanioses em humanos (AKHOUNDI et \n\nal., 2016). A transmiss\u00e3o ocorre durante o repasto sangu\u00edneo de f\u00eameas de \n\nflebotom\u00edneos infectados do g\u00eanero Lutzomyia ou Phlebotomus (SHARMA; SINGH, \n\n2008). \n\nAs op\u00e7\u00f5es terap\u00eauticas para o tratamento das leishmanioses s\u00e3o restritas, tendo \n\ncomo f\u00e1rmacos de primeira escolha os antimoniais pentavalentes, descobertos na \n\nd\u00e9cada de 20. O tratamento \u00e9 longo, t\u00f3xico e os efeitos colaterais s\u00e3o graves e \n\npersistentes e ainda apresenta baixa efic\u00e1cia devido a circula\u00e7\u00e3o de cepas resistentes. \n\nAnfotericina B e suas formula\u00e7\u00f5es lipossomais, pentamidina, paromomicina e miltefosina \n\nv\u00eam sendo empregados em terapias de segunda escolha (ALAVI-NAINI; FAZAELI; \n\nO\u2019DEMPSEY, 2012; FR\u00c9ZARD; DEMICHELI; RIBEIRO, 2009), por\u00e9m estes tamb\u00e9m \n\nexibem alta toxicidade. H\u00e1 v\u00e1rios problemas envolvidos com o arsenal terap\u00eautico para \n\nas leishmanioses, como a elevada toxicidade dos f\u00e1rmacos, os custos e vias de \n\nadministra\u00e7\u00e3o inconvenientes e surgimento de resist\u00eancia mostrando a necessidade de \n\ndescoberta de novos f\u00e1rmacos. Sendo assim, a busca por novos compostos mais \n\neficazes e mais seletivos para o parasito s\u00e3o atrativos no desenvolvimento de novos \n\ncandidatos a f\u00e1rmacos com baixa toxicidade aos pacientes. Compostos derivados de \n\nfuroxanos e benzofuroxanos v\u00eam sendo descritos por diversas bioatividades, incluindo \n\nsuas atividades leishmanicida e tripanocida (BEN\u00cdTEZ et al., 2014; BOIANI et al., 2008; \n\nCASTRO et al., 2009; HERN\u00c1NDEZ et al., 2013; PORCAL et al., 2008; SERAFIM et al., \n\n2014). Autores relatam enzimas de Leishmania e Trypanosoma cruzi como os potenciais \n\nalvos de a\u00e7\u00e3o destes compostos, podendo ser relacionado com sua atividade biol\u00f3gica. \n\n(ASCENZI et al., 2004; IFA et al., 2000; ROMEIRO et al., 2009). Ressalta-se ainda, o \n\npotencial de furoxanos em atuar como compostos doadores de \u00f3xido n\u00edtrico, uma \n\n\n\n16 \n \n\nimportante mol\u00e9cula efetora na elimina\u00e7\u00e3o da Leishmania (ZOU et al., 2011).  Portanto, \n\neste trabalho visa avaliar o potencial leishmanicida in vitro e in vivo de novos derivados \n\nde furoxano e benzofuroxano, bem como identificar seus poss\u00edveis mecanismos de a\u00e7\u00e3o.  \n\n  \n\n\n\n113 \n \n\n7 CONCLUS\u00d5ES  \n\n \n\nForam testados 11 derivados furox\u00e2nicos e 4 derivados benzofurox\u00e2nicos em \n\nformas promastigotas e amastigotas de L. (L.) amazonensis, L. (L.) mexicana e L. (L.) \n\ninfantum, bem como a citotoxicidade a macr\u00f3fagos peritoneais murinos. O composto 14e \n\nmostrou ser o mais promissor ao final dos ensaios in vitro, exibindo valores de EC50 e IS \n\npromissores (EC50-AMA = 8,2; 5,7 e 3,1 \u00b5M; e IS2 = 25,3; 25,4 e 66,4 em L. (L.) \n\namazonensis, L. (L.) mexicana e L. (L.) infantum, respectivamente). Os estudos \n\nenvolvendo os prov\u00e1veis mecanismos de a\u00e7\u00e3o do 14e foram direcionados baseando-se \n\nna estrutura qu\u00edmica da mol\u00e9cula. Estes estudos mostraram que este composto inibe a \n\nrCPB2.8 de L. (L.) mexicana (IC50 = 1,0 \u00b5M).  Adicionalmente, ensaios com linhagens \n\nnocautes de ciste\u00edno proteases de L. (L.) mexicana mostram ainda o poss\u00edvel \n\nenvolvimento da CPA de Leishmania na atividade do 14e. De fato, se CPB2.8 fosse o \n\n\u00fanico alvo de a\u00e7\u00e3o de 14e, o aumento na oferta de CPB2.8 da linhagem superexpressora \n\n(?cpb+pXcpb2.8) deveria \u201cdiluir\u201d os efeitos de 14e, o que poderia ser verificado atrav\u00e9s \n\nde um aumento de EC50-AMA; no entanto, verificou-se que esta linhagem se mostrou mais \n\nsuscept\u00edvel. Isto pode ser devido ao fato que o 14e possa ter outros alvos de a\u00e7\u00e3o em \n\nLeishmania. Corrobora-se a isso, o insucesso no desenvolvimento de cepas de diferentes \n\nesp\u00e9cies de Leishmania resistentes ao 14e. Os parasitos mesmo ap\u00f3s 20 passagens de \n\ncultivo in vitro na presen\u00e7a do composto n\u00e3o apresentaram altera\u00e7\u00e3o significativa em seu \n\npadr\u00e3o de susceptibilidade ao 14e. Os estudos preliminares adicionais revelaram outras \n\nvias de envolvimento no mecanismo de a\u00e7\u00e3o do 14e, sendo assim verificou-se uma \n\nprov\u00e1vel implica\u00e7\u00e3o de seu precursor (13b) nas altera\u00e7\u00f5es na homeostase do c\u00e1lcio. Vale \n\nressaltar, que o 14e exibe atividade pH dependente, sendo hidrolisado ao seu alde\u00eddo \n\nprecursor em pH \u00e1cido. Para validarmos o 14e como um hit a ser explorado e modificado \n\nquimicamente, avaliou-se ainda seu potencial leishmanicida in vivo. O tratamento de \n\nhamsters infectados com L. (L.) infantum com uma dose de 3,0 mg/Kg/dia do 14e levou \n\na uma redu\u00e7\u00e3o significativa da carga parasit\u00e1ria no ba\u00e7o (49,9%) e f\u00edgado (54,2%), esses \n\ndados corroboram com as an\u00e1lises histopatol\u00f3gicas, as quais revelaram uma redu\u00e7\u00e3o de \n\nc\u00e9lulas inflamat\u00f3rias no f\u00edgado. Adicionalmente, n\u00e3o se verificaram efeitos colaterais \n\nt\u00f3xicos pelas an\u00e1lises toxicol\u00f3gicas e histopatol\u00f3gicas realizadas. Ao final, constata-se \n\n\n\n114 \n \n\nque o composto 14e deve ser investigado como uma mol\u00e9cula promissora no tratamento \n\ndas leishmanioses.  \n\n  \n\n\n\n115 \n \n\nREFER\u00caNCIAS  \n\n \n\nAFONSO, L. C.; SCOTT, P. Immune responses associated with susceptibility of \nC57BL/10 mice to Leishmania amazonensis. Infection and Immunity, v. 61, n. 7,        \np. 2952-2959, 1993.  \n\nAKHOUNDI, M. et al. A historical overview of the classification, evolution, and dispersion \nof Leishmania parasites and sandflies. PLoS Neglected Tropical Diseases, 2016. \ndoi:10.1371/journal.pntd.0004349.  \n\nALAVI-NAINI, R.; FAZAELI, A.; O\u2019DEMPSEY, T. Topical treatment modalities for old \nworld cutaneous leishmaniasis: a review. Prague Medical Report, v. 113, n. 2,             \np. 105-118, 2012. \n\nALEXANDER, J.; SATOSKAR,  A R.; RUSSELL, D. G. Leishmania species: models of \nintracellular parasitism. Journal of Cell Science, v. 112, p. 2993-3002, 1999.  \n\nALMEIDA, L. de et al. Nanotechnological strategies for treatment of leishmaniasis-a \nreview. Journal of Biomedical Nanotechnology, v. 13, n. 2, p. 117-242, 2017.  \n\nALSFORD, S. A. M. et al. Genetic dissection of drug resistance in Trypanosomes. \nParasitology, v. 140, p. 1478-1491, 2013.  \n\nALVAR, J.; CROFT, S.; OLLIARO, P. Chemotherapy in the treatment and control of \nleishmaniasis. Advances in Parasitology, v. 61, p. 223-274, 2006.  \n\nANTOINE, J. et al. The biogenesis and properties of the parasitophorous vacuoles that \nharbour Leishmania in murine macrophages. Trends in Microbiology, v. 7, n. 10,         \np. 392-401, 1998.  \n\nASCENZI, P. et al. Inactivation of parasite cysteine proteinases by the NO-donor 4-\n(phenylsulfonyl)-3-((2-(dimethylamino)ethyl)thio)-furoxan oxalate. Biochimica et \nBiophysica Acta, v. 1703, p. 69-77, 2004.  \n\nASSIS, R. R. de et al. Glycoconjugates in new world species of Leishmania: \npolymorphisms in lipophosphoglycan and glycoinositolphospholipids and interaction with \nhosts. Biochimica et Biophysica Acta, v. 1820, n. 9, p. 1354-1365, 2012.  \n\nAWASTHI, A. et al. Immune response to Leishmania infection. Indian Journal of \nMedical Research, v. 119, p. 238-258, 2004.  \n\nBALA\u00d1A-FOUCE, R. et al. Role of trypanosomatid\u2019s arginase in polyamine biosynthesis \nand pathogenesis. Molecular &amp; Biochemical Parasitology, v. 181, p. 85-93, 2012.  \n\nBALASEGARAM, M. et al. Liposomal amphotericin B as a treatment for human \nleishmaniasis. Expert Opinion on Emerging Drugs, v. 17, n. 4, p. 493-510, 2012.  \n\n \n\n\n\n116 \n \n\nBARRETT, M. P.; CROFT, S. L. Management of trypanosomiasis and leishmaniasis. \nBritish Medical Bulletin, v. 104, n. 1, p. 175-196, 2012.  \n\nBARROS-ALVAREZ, X. et al. Glycosomal targets for anti-trypanosomatid drug \ndiscovery. Current Medicinal Chemistry, v. 21, n. 15, p. 1679-1706, 2014.  \n\nBASU, J. M. et al. Inhibition of ABC transporters abolishes antimony resistance in \nLeishmania infection. Antimicrobial Agents and Chemotherapy, v. 52, n. 3,               \np. 1080-1093, 2008.  \n\nBEATTIE, L.; KAYE, P. M. Leishmania-host interactions: what has imaging taught us? \nCellular Microbiology, v. 13, n. 11, p. 1659-1667, 2011.  \n\nBEAUMONT, K.; SMITH, D. A. Does human pharmacokinetic prediction add significant \nvalue to compound selection in drug discovery research? Current Opinion on Drug \nDiscovery Development, v. 12, n. 1, p. 61-71, 2009.  \n\nBEN\u00cdTEZ, D. et al. Initial studies on mechanism of action and cell death of active N-\noxide-containing heterocycles in Trypanosoma cruzi epimastigotes in vitro. \nParasitology, v. 141, n. 5, p. 682-696, 2014.  \n\nBENJAMIN, N.; VALLANCE, P. Plasma nitrite as a marker of nitric oxide production. \nLancet, v. 344, n. 8927, p. 960, 1994.  \n\nBERMAN, J. D.; DWYER, D. M.; WYLER, D. J. Multiplication of Leishmania in human \nmacrophages in vitro. Infection and Immunity, v. 26, n. 1, p. 375-379, 1979.  \n\nBERMAN, J. D. et al. Antileishmanial activity of liposome-encapsulated amphotericin B \nin hamsters and monkeys. Antimicrobial Agents and Chemotherapy, v. 30, n. 6,       \np. 847-851, 1986.  \n\nBERNIER, R.; TURCO, S. J.; OLIVIER, M. Activation of human immunodeficiency virus \ntype 1 in monocytoid cells by the protozoan parasite Leishmania donovani. Journal of \nVirology, v. 69, n. 11, p. 7282-7285, 1995.  \n\nBES, D. F. et al. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. \nPediatric Infectious Disease Journal, v. 33, p. 198-206, 2014.  \n\nBESSON-BARD, A.; PUGIN, A.; WENDEHENNE, D. New insights into nitric oxide \nsignaling in plants. Annual Review of Plant Biology, v. 59, p. 21-39, 2008.  \n\nBESTEIRO, S. et al. Protein turnover and differentiation in Leishmania. International \nJournal for Parasitology, v. 37, p. 1063-1075, 2007.  \n\nBOCEDI, A. et al. Trypanothione efficiently intercepts nitric oxide as a harmless iron \ncomplex in trypanosomatid parasites. The FASEB Journal, v. 24, p. 1035-1042, 2010.  \n\nBOIANI, L. et al. Furoxan-, alkylnitrate-derivatives and related compounds as anti-\ntrypanosomatid agents: mechanism of action studies. Bioorganic and Medicinal \nChemistry, v. 16, p. 7900-7907, 2008.  \n\n\n\n117 \n \n\nBONATE, P. L.; REITH, K.; WEIR, S. Drug interactions at the renal level. Clinical \nPharmacokinetics, v. 34, n. 5, p. 375-404, 1998.  \n\nBOTERO AGUIRRE, J. P.; RESTREPO HAMID, A. M. Amphotericin B deoxycholate \nversus liposomal amphotericin B: effects on kidney function. The Cochrane Database \nof Systematic Reviews, 2015. doi:10.1002/14651858.CD010481.pub2.  \n\nBURCHMORE, R. J.; BARRETT, M. P. Life in vacuoles-nutrient acquisition by \nLeishmania amastigotes. International Journal for Parasitology, v. 31, p. 1311-1320, \n2001. \n\nCALLAHAN, H. L. et al. An axenic amastigote system for drug screening. Antimicrobial \nAgents and Chemotherapy, v. 41, n. 4, p. 818-822, 1997.  \n\nCALVINO, R. et al. Antimicrobial properties of some furazan and furoxan derivatives. \nEuropean Journal of Medicinal Chemistry, v. 15, n. 5, p. 485-487, 1980.  \n\nCALVINO, R. et al. Syntheses, structures and antimicrobial properties of some \nhalogenofuroxans and related furazans. Archiv der Pharmazie, v. 317, p. 695-701, \n1984.  \n\nCAMERON, P. et al. Inhibition of lipopolysaccharide-induced macrophage IL-12 \nproduction by Leishmania mexicana amastigotes: the role of cysteine peptidases and \nthe NF-kappaB signaling pathway. Journal of Immunology, v. 173, n. 5, p. 3297-3304, \n2004.  \n\nCARVALHO, S. A. et al. Design and synthesis of new (E)-cinnamic N-acylhydrazones as \npotent antitrypanosomal agents. European Journal of Medicinal Chemistry, v. 54,        \np. 512-521, 2012.  \n\nCASTRO, D. et al. Anti-trypanosomatid benzofuroxans and deoxygenated analogues: \nsynthesis using polymer-supported triphenylphosphine, biological evaluation and \nmechanism of action studies. European Journal of Medicinal Chemistry, v. 44,         \np. 5055-5065, 2009.  \n\nCAVALLI, A.; BOLOGNESI, M. L. Neglected tropical diseases: multi-target-directed \nligands in the search for novel lead candidates against Trypanosoma and Leishmania. \nJournal of Medicinal Chemistry, v. 52, n. 23, p. 7339-7359, 2009.  \n\nCELIS, R.; ROMO, D.; ROMERO, E. Blind colour separation of H&amp;E stained histological \nimages by linearly transforming the colour space. Journal of Microscopy, v. 260, n. 3, \np. 377-388, 2015.  \n\nCERECETTO, H.; PORCAL, W. Pharmacological properties of furoxans and \nbenzofuroxans: recent developments. Mini Reviews in Medicinal Chemistry, v. 5, n. 1, \np. 57-71, 2005.  \n\nCESTA, M. Normal structure, function, and histology of the spleen. Toxicologic \nPathology, v. 34, n. 5, p. 455-465, 2006.  \n\n\n\n118 \n \n\nCHANG, K. P.; DWYER, D. M. Multiplication of a human parasite (Leishmania donovani) \nin phagolysosomes of hamster macrophages in vitro. Science, v. 193, n. 4254,              \np. 678-680, 1976.  \n\nCHAPPUIS, F. et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment \nand control? Nature Reviews Microbiology, v. 5, n. 11, p. 873-882, 2007.  \n\nCHATELAIN, E.; IOSET, J. R. Drug discovery and development for neglected diseases: \nthe DNDi model. Drug Design, Development and Therapy, v. 5, p. 175-181, 2011.  \n\nCHELUCCI, R. C. et al. Antiplatelet and antithrombotic activities of non-steroidal anti-\ninflammatory drugs containing an N-acyl hydrazone subunit. Molecules, v. 19,              \np. 2089-2099, 2014.  \n\nCHOI, M.; YU, J. Who neglects neglected tropical diseases? - korean perspective. \nJournal of Korean Medical Science, v. 30, p. S122-S130, 2015.  \n\nCHUNGE, C. N. et al. Treatment of visceral leishmaniasis in Kenya by aminosidine \nalone or combined with sodium stibogluconate. Transactions of the Royal Society of \nTropical Medicine and Hygiene, v. 84, n. 2, p. 221-225, 1990.  \n\nCOELHO, A. C. et al. Leishmania is not prone to develop resistance to tamoxifen. \nInternational Journal for Parasitology: Drugs and Drug Resistance, v. 5, p. 77-83, \n2015.  \n\nCOLONNA, M.; FACCHETTI, F. TREM-1 (Triggering Receptor Expressed on Myeloid \nCells): a new player in acute inflammatory responses. The Journal of Infectious \nDiseases, v. 1, p. 397-401, 2003.  \n\nCOLOTTI, G.; ILARI, A. Polyamine metabolism in Leishmania: from arginine to \ntrypanothione. Amino Acids, v. 40, n. 2, p. 269-285, 2011.  \n\nCOOMBS, G. H.; MOTTRAM, J. C. Parasite proteinases and amino acid metabolism: \npossibilities for chemotherapeutic exploitation. Parasitology, v. 114, p. S61-S80, 1997.  \n\nCORRAL, M. J. et al. Allicin induces calcium and mitochondrial dysregulation causing \nnecrotic death in Leishmania. PLoS Neglected Tropical Diseases, v. 10, n. 3, 2016. \ndoi:10.1371/journal.pntd.0004525.  \n\nCROFT, S. L. Public-private partnership: from there to here. Transactions of the Royal \nSociety of Tropical Medicine and Hygiene, v. 995, p. S9-S14, 2005.  \n\nCROFT, S. L.; OLLIARO, P. Leishmaniasis chemotherapy-challenges and opportunities. \nClinical Microbiology and Infection, v. 17, n. 10, p. 1478-1483, 2011.  \n\nCROFT, S. L.; SUNDAR, S.; FAIRLAMB, A. H. Drug resistance in leishmaniasis. \nClinical Microbiology Reviews, v. 19, n. 1, p. 111-126, 2006.  \n\n \n\n \n\n\n\n119 \n \n\nDAS, A.; ALI, N. Combining cationic liposomal delivery with MPL-TDM for cysteine \nprotease cocktail vaccination against Leishmania donovani: evidence for antigen \nsynergy and protection. PLoS Neglected Tropical Diseases, v. 8, n. 8, 2014.            \ndoi:10.1371/journal.pntd.000309.  \n\nDEN BOER, M. et al. Leishmaniasis impact and treatment access. Clinical \nMicrobiology and Infection, v. 17, p. 1471-1477, 2011.  \n\nDENISE, H. et al. Expression of multiple CPB genes encoding cysteine proteases is \nrequired for Leishmania mexicana virulence in vivo. Infection and Immunity, v. 71, n. 6, \np. 3190-3195, 2003.  \n\nDENNY, P. W.; STEEL, P. G. Yeast as a potential vehicle for neglected tropical disease \ndrug discovery. Journal of Biomolecular Screening, v. 20, n. 1, p. 56-63, 2015.  \n\nDESJEUX, P.; ALVAR, J. Leishmania/HIV co-infections: epidemiology in Europe. \nAnnnals of Tropical Medicine &amp; Parasitology, v. 97, n. 1, p. 3-15, 2003.  \n\nDIXON, M.; WEBB, E. Enzymes. 2nd ed. London: Longmans, 1964. \n\nDUARTE, C. D.; BARREIRO, E. J.; FRAGA, C. A. M. Privileged structures: a useful \nconcept for the rational design of new lead drug candidates. Mini Reviews in Medicinal \nChemistry, v. 7, n. 11, p. 1108-1119, 2007.  \n\nDUTRA, L. A. et al. Leishmanicidal activities of novel synthetic furoxan and \nbenzofuroxan derivatives. Antimicrobial Agents and Chemotherapy, v. 58, n. 8,        \np. 4837-4847, 2014.  \n\nEL HAG, I. A. et al. Liver morphology and function in visceral leishmaniasis (Kala-azar). \nJournal of Clinical Phatology, v. 47, p. 547-551, 1994. \n\nEL-ON, J. et al. Topical treatment of cutaneous leishmaniasis. Journal of Investigative \nDermatology, v. 87, n. 2, p. 284-288, 1986.  \n\nEMANUELLI, M. P. et al. Concentra\u00e7\u00e3o s\u00e9rica de fosfatase alcalina, gama-glutamil \ntransferase, ur\u00e9ia e creatinina em coelhos (Oryctolagus cuniculus). Ci\u00eancia Animal \nBrasileira, v. 9, n. 1, p. 251-255, 2008.  \n\nENGWERDA, C. R.; ATO, M.; KAYE, P. M. Macrophages, pathology and parasite \npersistence in experimental visceral leishmaniasis. Trends in Parasitology, v. 20,       \nn. 11, p. 524-530, 2004.  \n\nESPITIA, C. M. et al. Transcriptional profiling of the spleen in progressive visceral \nleishmaniasis reveals mixed expression of type 1 and type 2 cytokine-responsive genes. \nBMC Imunology, v. 15, n. 1, 2014. doi:10.1186/s12865-014-0038-z.  \n\nFENG, B. et al. Renal clearance in drug discovery and development: molecular \ndescriptors, drug transporters and disease state. Expert Opinion on Drug Metabolism \n&amp; Toxicology, v. 6, n. 8, p. 939-952, 2010.  \n\n \n\n\n\n120 \n \n\nFERREIRA, C. D. S. et al. Thiol-induced reduction of antimony(V) into antimony(III): a \ncomparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. \nBioMetals, v. 16, p. 441-446, 2003.  \n\nFRAGA, C. A. M.; BARREIRO, E. J. Medicinal chemistry of N-acylhydrazones: new \nlead-compounds of analgesic, antiinflammatory and antithrombotic drugs. Current \nMedicinal Chemistry, v. 13, p. 167-198, 2006.  \n\nFR\u00c9ZARD, F.; DEMICHELI, C.; RIBEIRO, R. R. Pentavalent antimonials: new \nperspectives for old drugs. Molecules, v. 14, n. 7, p. 2317-2336, 2009.  \n\nFUMAROLA, L.; SPINELLI, R.; BRANDONISIO, O. In vitro assays for evaluation of drug \nactivity against Leishmania spp. Research in Microbiology, v. 155, n. 4, p. 224-230, \n2004.  \n\nGALLI, U. et al. Synthesis and antimalarial activities of some furoxan sulfones and \nrelated furazans. European Journal of Medicinal Chemistry, v. 40, p. 1335-1340, \n2005.  \n\nG\u00d3MEZ-LECH\u00d3N, M. J. et al. Mechanism-based selection of compounds for the \ndevelopment of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP \nproject. Toxicology In Vitro, v. 24, n. 7, p. 1879-1889, 2010.  \n\nGONZ\u00c1LEZ, U. et al. Interventions for american cutaneous and mucocutaneous \nleishmaniasis. The Cochrane Database of Systematic Reviews, v. 15, n. 2, 2009.    \ndoi:10.1002/14651858.CD004834.pub2.  \n\nGOTO, H.; LINDOSO, J. A. L. Current diagnosis and treatment of cutaneous and \nmucocutaneous leishmaniasis. Expert Reviews, v. 8, n. 4, p. 419-433, 2010.  \n\nGREEN, L. C. et al. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. \nAnalytical Biochemistry, v. 126, p. 131-138, 1982.  \n\nGRIMALDI JUNIOR, G.; TESH, R. B. Leishmaniases of the new world: current concepts \nand implications for future research. Clinical Microbiology Reviews, v. 6, n. 3,            \np. 230-250, 1993.  \n\nHAMILL, R. J. Amphotericin B formulations: a comparative review of efficacy and \ntoxicity. Drugs, v. 73, p. 919-934, 2013.  \n\nHAMILTON, C. J. et al. Time-dependent inhibitors of trypanothione reductase: \nanalogues of the spermidine alkaloid lunarine and related natural products. Bioorganic \nand Medicinal Chemistry, v. 14, p. 2266-2278, 2005.  \n\nHEBY, O.; PERSSON, L.; RENTALA, M. Targeting the polyamine biosynthetic enzymes: \na promising approach to therapy of African sleeping sickness, Chagas\u2019 disease, and \nleishmaniasis. Amino Acids, v. 33, p. 359-366, 2007.  \n\n \n\n\n\n121 \n \n\n \n\nHERN\u00c1NDEZ, P. et al. Hybrid furoxanyl N-acylhydrazone derivatives as hits for the \ndevelopment of neglected diseases drug candidates. European Journal of Medicinal \nChemistry, v. 59, p. 64-74, 2013.  \n\nHESS, D. T. et al. Protein S-nitrosylation: purview and parameters. Nature Reviews \nMolecular Cell Biology, v. 6, n. 2, p. 150-166, 2005.  \n\nHORTA, M. F. et al. Reactive oxygen species and nitric oxide in cutaneous \nleishmaniasis. Jounal of Parasitology Research, v. 2012, 2012.                                \ndoi:10.1155/2012/203818.  \n\nHOTEZ, P. J.; SAVIOLI, L.; FENWICK, A. Neglected tropical diseases of the middle east \nand north africa: review of their prevalence, distribution, and opportunities for control. \nPLoS Neglected Tropical Diseases, v. 6, n. 2, 2012. \ndoi:10.1371/journal.pntd.0001475.  \n\nIFA, D. R. et al. A possible molecular mechanism for the inhibition of cysteine proteases \nby salicylaldehyde N-acylhydrazones and related compounds. Journal of Molecular \nStructure: THEOCHEM, v. 505, p. 11-17, 2000.  \n\nILARI, A. et al. An update on structural insights into the enzymes of the polyamine-\ntrypanothione pathway: targets for new drugs against leishmaniasis. Future Medicinal \nChemistry, v. 9, n. 1, p. 61-77, 2017.  \n\nINGAWALE, D. K.; MANDLIK, S. K.; NAIK, S. R. Models of hepatotoxicity and the \nunderlying cellular, biochemical and immunological mechanism(s): a critical discussion. \nEnvironmental Toxicology and Pharmacology, v. 37, n. 1, p. 118-133, 2014.  \n\nKAISER, M. et al. Repurposing of the open access malaria box for kinetoplastid \ndiseases identifies novel active scaffolds against Trypanosomatids. Journal of \nBiomolecular Screening, 2015. doi:10.1177/1087057115569155.  \n\nKAPPAGODA, S.; SINGH, U.; BLACKBURN, B. G. Antiparasitic therapy. Mayo Clinical \nProceedings, v. 86, n. 6, p. 561-583, 2011.  \n\nKAR, S.; SHARMA, G.; DAS, P. K. Fucoidan cures infection with both antimony-\nsusceptible and-resistant strains of Leishmania donovani through Th1 response and \nmacrophage-derived oxidants. Journal of Antimicrobial Chemotherapy, v. 66, n. 3,    \np. 618-625, 2011.  \n\nKATSUNO, K. et al. Hit and lead criteria in drug discovery for infectious diseases of the \ndeveloping world. Nature Reviews Drug Discovery, v. 14, n. 11, p. 751-758, 2015.  \n\nKAUR, G.; RAJPUT, B. Comparative analysis of the omics technologies used to study \nantimonial, amphotericin B, and pentamidine resistance in Leishmania. Journal of \nParasitology Research, v. 2014, p. 1-11, 2014.  \n\n \n\n\n\n122 \n \n\nKAYE, P.; SCOTT, P. Leishmaniasis: complexity at the host-pathogen interface. Nature \nReviews Microbiology, v. 9, n. 8, p. 604-615, 2011.  \n\nKEDZIERSKI, L. Leishmaniasis. Landes Bioscience, v. 7, n. 11, p. 1204-1214, 2011.  \n\nKHALILI, H.; BAIRAMI, S.; KARGAR, M. Antibiotics induced acute kidney injury: \nincidence, risk factors, onset time and outcome. Acta Medica Iranica, v. 51, n. 12,       \np. 871-878, 2013.  \n\nKHANNA, I. Drug discovery in pharmaceutical industry: productivity challenges and \ntrends. Drug Discovery Today, v. 17, n. 19/20, p. 1088-1102, 2012.  \n\nKILLICK-KENDRICK, R. The life-cycle of Leishmania in the sandfly with special \nreference to the form infective to the vertebrate host. Annales de Parasitologie \nHumaine et Compare?e, v. 65, p. 37-42, 1990.  \n\nLAINSON, R.; SHAW, J. J. Evolution, classification and geographical distribution. In: \nPETERS, W.; KILLICK-KENDRICK, R. (Ed.). The leishmaniasis in biology and \nmedicine. London: Academic Press, 1987. p. 1-120.  \n\nLANIADO-LABOR\u00cdN, R.; CABRALES-VARGAS, M. N. Amphotericin B: side effects and \ntoxicity. Revista Iberoamericana de Micolog\u00eda, v. 26, n. 4, p. 223-227, 2009.  \n\nLEANDRO, C.; CAMPINO, L. Leishmaniasis: efflux pumps and chemoresistance. \nInternational Journal of Antimicrobial Agents, v. 22, n. 3, p. 352-357, 2003.  \n\nLEHNINGER, A.; NELSON, D.; COX, M. Princ\u00edpios de bioqu\u00edmica. 3. ed. S\u00e3o Paulo: \nSarvier, 2003. \n\nLEMESRE, J. L. et al. Leishmania spp.: nitric oxide-mediated metabolic inhibition of \npromastigote and axenically grown amastigote forms. Experimental Parasitology,       \nv. 86, p. 58-68, 1997.  \n\nLEZAMA-D\u00c1VILA, C. M. et al. Leishmanicidal activity of two naphthoquinones against L. \ndonovani. Biological and Phamaceutical Bulletin, v. 35, n. 10, p. 1761-1764, 2012.  \n\nLI, R. et al. Structure-based design of parasitic protease inhibitors. Bioorganic and \nMedicinal Chemistry, v. 4, n. 9, p. 1421-1427, 1996.  \n\nLIM, A. Y. L. et al. Histopathology and biochemistry analysis of the interaction between \nsunitinib and paracetamol in mice. BMC Pharmacology, v. 10, n. 14, 2010.                 \ndoi:10.1186/1471-2210-10-14.  \n\nLIMA, A. P.; REIS, F. C.; COSTA, T. F. Cysteine peptidase inhibitors in trypanosomatid \nparasites. Current Medicinal Chemistry, v. 20, n. 25, p. 3152-3173, 2013.  \n\nLIMA, H. C.; BLEYENBERG, J. A.; TITUS, R. G. A simple method for quantifying \nLeishmania in tissues of infected animals. Parasitology Today, v. 13, n. 2, p. 80-82, \n1997.  \n\n \n\n\n\n123 \n \n\nLINDOSO, J. A. et al. Visceral leishmaniasis and HIV coinfection in Latin America. PLoS \nNeglected Tropical Diseases, 2014. doi:10.1371/journal.pntd.0003136.  \n\nMAEKAWA, Y. et al. Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment \nwith cathepsin B inhibitor in experimental leishmaniasis. The Journal of Immunology, \nv. 161, p. 2120-2127, 1998.  \n\nMALTEZOU, H. C. Drug resistance in visceral leishmaniasis. Journal of Biomedicine \nand Biotechnology, v. 2010, 2010. doi:10.1155/2010/617521.  \n\nMANANDHAR, K. DAS et al. Antileishmanial activity of nano-amphotericin B \ndeoxycholate. Journal of Antimicrobial Chemotherapy, v. 62, n. 2, p. 376-380, 2008.  \n\nMASSARICO SERAFIM, R. A. et al. Design, synthesis and biological evaluation of \nhybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and \nselective anti-Trypanosoma cruzi activity. European Journal of Medicinal Chemistry, \nv. 82, p. 418-425, 2014.  \n\nMATTOS, D. G. J. et al. Aspectos cl\u00ednicos e de laborat\u00f3rio de c\u00e3es soropositivos para \nleishmaniose. Arquivo Brasileiro de Medicina Veterin\u00e1ria e Zootecnia, v. 56, n. 1,   \np. 119-122, 2004.  \n\nMAU\u00cbL, J.; RANSIJN, A. Leishmania spp.: mechanisms of toxicity of nitrogen oxidation \nproducts. Experimental Parasitology, v. 87, p. 98-111, 1997.  \n\nMcCONVILLE, M. J.; NADERER, T. Metabolic pathways required for the intracellular \nsurvival of Leishmania. Annual Review of Microbiology, v. 65, p. 543-561, 2011.  \n\nMcGWIRE, B. S.; SATOSKAR, A. R. Leishmaniasis: clinical syndromes and treatment. \nQJM: Monthly Journal of the Association of Physicians, v. 107, n. 1, p. 7-14, 2014.  \n\nMcKERROW, J. H. et al. Proteases in parasitic diseases. Annual Review of \nPathology: Mechanisms of Disease, v. 1, n. 1, p. 497-536, 2006.  \n\nMELBY, P. C. et al. The hamster as a model of human visceral leishmaniasis: \nprogressive disease and impaired generation of nitric oxide in the face of a prominent \nTh1-like cytokine response. Journal of Imunology, v. 166, n. 3, p. 1912-1920, 2001.  \n\nMELLO, T. F. P. de et al. Leishmanicidal activity of synthetic chalcones in Leishmania \n(Viannia) braziliensis. Experimental Parasitology, v. 136, p. 27-34, 2014.  \n\nMELO, E. C. de; FORTALEZA, C. M. C. B. Challenges in the therapy of visceral \nleishmaniasis in Brazil: a public health perspective. Journal of Tropical Medicine,       \nv. 2013, 2013. doi:10.1155/2013/319234.  \n\nMELO, T. R. F. de et al. Pharmacological evaluation and preparation of nonsteroidal \nanti-inflammatory drugs containing an N-acyl hydrazone subunit. International Journal \nof Molecular Sciences, v. 15, p. 5821-5837, 2014.  \n\n \n\n\n\n124 \n \n\nMICHELS, P. A.; AVIL\u00c1N, L. The NAD+ metabolism of Leishmania, notably the enzyme \nnicotinamidase involved in NAD+ salvage, offers prospects for development of anti-\nparasite chemotherapy. Molecular Microbiology, v. 82, n. 1, p. 4-8, 2011.  \n\nMILLET, P. Status of research and development for control of tropical diseases: \nhypocrisy, indifference or lack of coordination. Medecine Tropicale, v. 66, n. 6,            \np. 542-548, 2006.  \n\nMOCK, D. J. et al. Leishmania induces survival, proliferation and elevated cellular dNTP \nlevels in human monocytes promoting acceleration of HIV co-infection. PLoS \nPathogens, v. 8, n. 4, 2012. doi:10.1371/journal.ppat.1002635. \n\nMOHAMED-AHMED, A. H. A.; BROCCHINI, S.; CROFT, S. L. Recent advances in \ndevelopment of amphotericin B formulations for the treatment of visceral leishmaniasis. \nCurrent Opinion in Infectious Diseases, v. 25, p. 695-702, 2012.  \n\nMOLYNEUX, D. H.; MALECELA, M. N. Neglected tropical diseases and the millennium \ndevelopment goals-why the \u201cother diseases\u201d matter: reality versus rhetoric. Parasites &amp; \nVectors, v. 4, n. 234, p. 1-13, 2011.  \n\nMOORE, E. M.; LOCKWOOD, D. N. Treatment of visceral leishmaniasis. Journal of \nGlobal Infectious Diseases, v. 2, n. 2, p. 151-158, 2010.  \n\nMORENO, S. N. J.; DOCAMPO, R. Calcium regulation in protozoan parasites. Current \nOpinion in Microbiology, v. 6, p. 359-364, 2003.  \n\nMOSHAGE, H. et al. Nitrite and nitrate determinations in plasma: a critical evaluation. \nClinical Chemistry, v. 41, p. 892-896, 1995.  \n\nMOSSER, D. M.; ROSENTHAL, L. A. Leishmania-macrophage interactions: multiple \nreceptors, multiple ligands and diverse cellular responses. Seminars in Cell Biology,   \nv. 4, n. 5, p. 315-322, 1993.  \n\nMOTTA, V. T. Bioqu\u00edmica cl\u00ednica para o laborat\u00f3rio: pr\u00edncipios e interpreta\u00e7\u00f5es.       \n4. ed. S\u00e3o Paulo: Robe, 2003.  \n\nMOTTRAM, J. C.; BROOKS, D. R.; COOMBS, G. H. Roles of cysteine proteinases of \nTrypanosomes and Leishmania in host-parasite interactions. Current Opinion in \nMicrobiology, v. 1, n. 4, p. 455-460, 1998.  \n\nMOTTRAM, J. C.; COOMBS, G. H.; ALEXANDER, J. Cysteine peptidases as virulence \nfactors of Leishmania. Current Opinion in Microbiology, v. 7, n. 4, p. 375-381, 2004.  \n\nMOTTRAM, J. C. et al. Evidence from disruption of the lmcpb gene array of Leishmania \nmexicana that cysteine proteinases are virulence factors. Proceedings of the National \nAcademy of Sciences of the United States of America, v. 93, n. 12, p. 6008-6013, \n1996.  \n\n \n\n\n\n125 \n \n\nMOTTRAM, J. C. et al. The multiple cpb cysteine proteinase genes of Leishmania \nmexicana encode isoenzymes that differ in their stage regulation and substrate \npreferences. Journal of Biological Chemistry, v. 272, n. 22, p. 14285-14293, 1997.  \n\nMOTTRAM, J. C. et al. Clan CD cysteine peptidases of parasitic protozoa. Trends in \nParasitology, v. 19, n. 4, p. 182-187, 2003.  \n\nMUELAS-SERRANO, S.; NOGAL-RUIZ, J. J.; G\u00d3MEZ-BARRIO, A. Setting of a \ncolorimetric method to determine the viability of Trypanosoma cruzi epimastigotes. \nParasitology Research, v. 86, p. 999-1002, 2000.  \n\nMULLER, J.; HEMPHILL, A. Drug target identification in intracellular and extracellular \nprotozoan parasites. Current Topics in Medicinal Chemistry, v. 11, n. 16,                   \np. 2029-2038, 2011.  \n\nNWAKA, S.; RIDLEY, R. G. Virtual drug discovery and development for neglected \ndiseases through public-private partnerships. Nature Reviews Drug discovery, v. 2,   \np. 919-928, 2003.  \n\nOLLIARO, P. L. Drug combinations for visceral leishmaniasis. Current Opinion in \nInfectious Diseases, v. 23, n. 6, p. 595-602, 2010.  \n\nOUELLETTE, M.; DRUMMELSMITH, J.; PAPADOPOULOU, B. Leishmaniasis: drugs in \nthe clinic, resistance and new developments. Drug Resistance Updates, v. 7,              \np. 257-266, 2004.  \n\nPACE, D. Leishmaniasis. Journal of Infection, v. 69, p. S10-S18, 2014.  \n\nPALATNIK-DE-SOUSA, C. B.; DAY, M. J. One health: the global challenge of epidemic \nand endemic leishmaniasis. Parasites &amp; Vectors, v. 4, n. 197, 2011.     \ndoi:10.1186/1756-3305-4-197.  \n\nPATOLE, S.; BURZA, S.; VARGHESE, G. M. Multiple relapses of visceral leishmaniasis \nin a patient with HIV in India: a treatment challenge. International Journal of \nInfectious Diseases, v. 25, p. 204-206, 2014.  \n\nP\u00c9COUL, B. New drugs for neglected diseases: from pipeline to patients. PLoS \nMedicine, v. 1, n. 1, p. 19-22, 2004.  \n\nPEDRIQUE, B. et al. The drug and vaccine landscape for neglected diseases (2000-11): \na systematic assessment. The Lancet Global Health, v. 1, p. 371-379, 2013.  \n\nPENDIN, D.; GREOTTI, E.; POZZAN, T. The elusive importance of being a \nmitochondrial Ca2+ uniporter. Cell Calcium, v. 55, p. 139-145, 2014.  \n\nP\u00c9REZ-VICTORIA, F. J. et al. Functional cloning of the miltefosine transporter: a novel \nP-type phospholipid translocase from Leishmania involved in drug resistance. The \nJournal of Biological Chemistry, v. 278, n. 50, p. 49965-49971, 2003.  \n\n \n\n\n\n126 \n \n\nPERSICHINI, T. et al. Nitric oxide inhibits the HIV-1 reverse transcriptase activity. \nBiochemical and Biophysical Research Communications, v. 258, n. 3, p. 624-627, \n1999.  \n\nPIMENTEL, I. A. S. et al. In vitro and in vivo activity of an organic tellurium compound on \nLeishmania (Leishmania) chagasi. PLoS ONE, v. 7, n. 11, 2012.                                 \ndoi:10.1371/journal.pone.0048780.  \n\nPOLLOCK, K. G. J. et al. The Leishmania mexicana cysteine protease, CPB2.8, induces \npotent Th2 responses. The Journal of Immunology, v. 170, p. 1746-1753, 2003.  \n\nPORCAL, W. et al. In vivo anti-chagas vinylthio-, vinylsulfinyl-, and vinylsulfonyl \nbenzofuroxan derivatives. Journal of Medicinal Chemistry, v. 50, n. 24, p. 6004-6015, \n2007.  \n\nPORCAL, W. et al. New trypanocidal hybrid compounds from the association of \nhydrazone moieties and benzofuroxan heterocycle. Bioorganic &amp; Medicinal \nChemistry, v. 16, p. 6995-7004, 2008.  \n\nPRAJAPATI, V. K. et al. In vitro antileishmanial drug susceptibility of clinical isolates \nfrom patients with indian visceral leishmaniasis - status of newly introduced drugs. \nAmerican Journal of Tropical Medicine and Hygiene, v. 87, n. 4, p. 655-657, 2012.  \n\nRAWLINGS, N. D.; MORTON, F. R.; BARRETT, A. J. MEROPS: the peptidase \ndatabase. Nucleic Acids Research, v. 34, p. 270-272, 2006.  \n\nREADY, P. D. Epidemiology of visceral leishmaniasis. Clinical Epidemiology, v. 6, n. 1, \np. 147-154, 2014.  \n\nREBELLO, K. M. et al. Cysteine proteinases from promastigotes of Leishmania (Viannia) \nbraziliensis. Parasitology Research, v. 106, n. 1, p. 95-104, 2009.  \n\nREITHINGER, R. et al. Cutaneous leishmaniasis. Clinics in Dermatology, v. 25, n. 2, \np. 203-211, 2007.  \n\nRODRIGUES, C. R. et al. CoMFA and HQSAR of acylhydrazide cruzain inhibitors. \nBioorganic and Medicinal Chemistry Letters, v. 12, p. 1537-1541, 2002.  \n\nROMEIRO, N. C. et al. Synthesis, trypanocidal activity and docking studies of novel \nquinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic \nand Medicinal Chemistry, v. 17, p. 641-652, 2009.  \n\nSAJID, M.; McKERROW, J. H. Cysteine proteases of parasitic organisms. Molecular \nand Biochemical Parasitology, v. 120, n. 1, p. 1-21, 2002.  \n\nSALVATI, L. et al. NO donors inhibit Leishmania infantum cysteine proteinase activity. \nBiochimica et Biophysica Acta, v. 1545, p. 357-366, 2001.  \n\nSANDERSON, S. J. et al. Expression and characterization of a recombinant cystein \nproteinase of Leishmania mexicana. Biochemical Journal, v. 347, p. 383-388, 2000.  \n\n\n\n127 \n \n\nSANDERSON, S. J. et al. Functional conservation of a natural cysteine peptidase \ninhibitor in protozoan and bacterial pathogens. FEBS Letters, v. 542, p. 12-16, 2003.  \n\nSANTOS, J. L. et al. Design, synthesis, and pharmacological evaluation of novel hybrid \ncompounds to treat sickle cell disease symptoms. Journal of Medicinal Chemistry,     \nv. 54, p. 5811-5819, 2011.  \n\nSANTOS, V. A. F. F. M. et al. Antiprotozoal sesquiterpene pyridine alkaloids from \nMaytenus ilicifolia. Journal of Natural Products, v. 75, n. 5, p. 991-995, 2012.  \n\nSANTOS, V. dos et al. Antiprotozoal activity of quinonemethide triterpenes from \nMaytenus ilicifolia (Celastraceae). Molecules, v. 18, n. 1, p. 1053-1062, 2013.  \n\nSEIFERT, K. Structures, targets and recent approaches in anti-leishmanial drug \ndiscovery and development. The Open Medicinal Chemistry Journal, v. 5, p. 31-39, \n2011.  \n\nSELZER, P. M. et al. Cysteine protease inhibitors as chemotherapy: lessons from a \nparasite target. Proceedings of the National Academy of Sciences of the United \nStates of America, v. 96, p. 11015-11022, 1999.  \n\nSERRANO-MART\u00cdN, X. et al. Amiodarone and miltefosine act synergistically against \nLeishmania mexicana and can induce parasitological cure in a murine model of \ncutaneous leishmaniasis. Antimicrobial Agents and Chemotherapy, v. 53, n. 12,       \np. 5108-5113, 2009.  \n\nSHAHA, C. Apoptosis in Leishmania species and its relevance to disease pathogenesis. \nThe Indian Journal of Medical Research, v. 123, n. 3, p. 233-244, 2006.  \n\nSHAKYA, N.; BAJPAI, P.; GUPTA, S. Therapeutic switching in Leishmania \nchemotherapy: a distinct approach towards unsatisfied treatment needs. Journal of \nParasitic Diseases, v. 35, n. 2, p. 104-112, 2011.  \n\nSHARMA, U.; SINGH, S. Insect vectors of Leishmania: distribution, physiology and their \ncontrol. Journal of Vector Borne Diseases, v. 45, n. 4, p. 255-272, 2008.  \n\nSHUKLA, A. K.; PATRA, S.; DUBEY, V. K. Deciphering molecular mechanism \nunderlying antileishmanial activity of Nyctanthes arbortristis, an Indian medicinal plant. \nJournal of Ethnopharmacology, v. 134, n. 3, p. 996-998, 2011.  \n\nSINGH, N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. \nIndian Jounal of Medical Research, v. 123, n. 3, p. 411-422, 2006.  \n\nSINGH, N.; KUMAR, M.; SINGH, R. K. Leishmaniasis: current status of available drugs \nand new potential drug targets. Asian Pacific Journal of Tropical Medicine, v. 5, n. 6, \np. 485-497, 2012.  \n\nSIQUEIRA NETO, J. L. et al. Antileishmanial high-throughput drug screening reveals \ndrug candidates with new scaffolds. PLoS Neglected Tropical Diseases, v. 4, n. 5, \n2010. doi:10.1371/journal.pntd.0000675. \n\n\n\n128 \n \n\nSODR\u00c9, F. L.; COSTA, J. C. B.; LIMA, J. C. C. Avalia\u00e7\u00e3o da fun\u00e7\u00e3o e da les\u00e3o renal: \num desafio laboratorial. Jornal Brasileiro de Patologia e Medicina Laboratorial,        \nv. 43, n. 5, p. 329-337, 2007.  \n\nSOOKOIAN, S.; PIROLA, C. J. Liver enzymes, metabolomics and genome-wide \nassociation studies: from systems biology to the personalized medicine. World Journal \nof Gastroenterology, v. 21, n. 3, p. 711-725, 2015.  \n\nSOONG, L.; HENARD, C. A.; MELBY, P. C. Immunopathogenesis of non-healing \nAmerican cutaneous leishmaniasis and progressive visceral leishmaniasis. Seminars in \nImmunopathology, v. 34, n. 6, p. 735-751, 2012.  \n\nSORBA, G. et al. Water soluble furoxan derivatives as NO prodrugs. Journal of \nMedicinal Chemistry, v. 40, p. 463-469, 1997.  \n\nSTANLEY, A. C.; ENGWERDA, C. R. Balancing immunity and pathology in visceral \nleishmaniasis. Immunology and Cell Biology, v. 85, n. 2, p. 138-147, 2007.  \n\nSTEERT, K. et al. ?-Ketoheterocycles as inhibitors of Leishmania mexicana cysteine \nprotease CPB. ChemMedChem, v. 5, n. 10, p. 1734-1748, 2010.  \n\nSTUART, K. et al. Kinetoplastids: related protozoan pathogens, different diseases. \nJournal of Clinical Investigation, v. 118, n. 4, p. 1301-1310, 2008.  \n\nSUNDAR, S.; CHAKRAVARTY, J. Liposomal amphotericin B and leishmaniasis: dose \nand response. Journal of Global Infectious Diseases, v. 7, p. 4267-4277, 2010.  \n\nSWENERTON, R. K. et al. Leishmania subtilisin is a maturase for the trypanothione \nreductase system and contributes to disease pathology. Journal of Biological \nChemistry, v. 285, n. 41, p. 31120-31129, 2010.  \n\nTARRANT, J.; MEYER, D.; KATAVOLOS, P. Use of optimized aminotransferase \nmethods in regulated preclinical studies. Veterinary Clinical Pathology, v. 42, n. 4,      \np. 535-538, 2013.  \n\nTEMPONE, A. G.; OLIVEIRA, C. M. de; BERLINK, R. G. S. Current approaches to \ndiscover marine antileishmanial natural products. Planta Medica, v. 77, p. 572-585, \n2011.  \n\nTER KUILE, B. H. Membrane-related processes and overall energy metabolism in \nTrypanosoma brucei and other Kinetoplastid species. Journal of Bioenergetics and \nBiomembranes, v. 26, n. 2, p. 167-172, 1994.  \n\nTIRONI, C. et al. Cytotoxic activity of a series of heteroaryl-ONN-azoxy-sulphones and \naryl sulphonylhydrazones. Anticancer Research, v. 9, n. 3, p. 609-610, 1989.  \n\nTIUMAN, T. S. et al. Recent advances in leishmaniasis treatment. International \nJournal of Infectious Diseases, v. 15, p. e525-e532, 2011.  \n\n \n\n\n\n129 \n \n\nTSIKAS, D. Analysis of nitrite and nitrate in biological fluids by assays based on the \nGriess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of \nresearch. Journal of Chromatography B: Analytical Technologies in the Biomedical \nand Life Sciences, v. 851, p. 51-70, 2007.  \n\nTUON, F. F. et al. Are there risk factors for acute renal failure in adult patients using \ndeoxycholate amphotericin B? Revista Iberoamericana de Micolog\u00eda, v. 30, n. 1,       \np. 21-24, 2013.  \n\nUENO, N.; WILSON, M. E. Receptor-mediated phagocytosis of Leishmania: implications \nfor intracellular survival. Trends in Parasitology, v. 28, n. 8, p. 335-344, 2012.  \n\nULIANA, S. R. B.; TRINCONI, C. T.; COELHO, A. C. Chemotherapy of leishmaniasis: \npresent challenges. Parasitology, p. 1-17, 2017. doi:10.1017/S0031182016002523.  \n\nUTZINGER, J. et al. Neglected tropical diseases: diagnosis, clinical management, \ntreatment and control. Swiss Medical Weekly, v. 142, p. 19-22, 2012.  \n\nVAN ASSCHE, T. et al. Leishmania-macrophage interactions: insights into the redox \nbiology. Free Radical Biology and Medicine, v. 51, n. 2, p. 337-351, 2011.  \n\nVANAERSCHOT, M. et al. Drug resistance in vectorborne parasites: multiple actors and \nscenarios for an evolutionary arms race. FEMS Microbiology Reviews, v. 38, n. 1,      \np. 41-55, 2014.  \n\nVAN GRIENSVEN, J.; DIRO, E. Visceral Leishmaniasis. Infectious Disease Clinics of \nNorth America, v. 26, n. 2, p. 309-322, 2012.  \n\nVARMA, M. V. S. et al. Physicochemical determinants of human renal clearance. \nJournal of Medicinal Chemistry, v. 52, p. 4844-4852, 2009.  \n\nVERESS, B. et al. Morphology of the spleen and lymph nodes in fatal visceral \nleishmaniasis. Immunology, v. 33, p. 605-610, 1977.  \n\nVIANNA, V. L. P.; TAKIYA, C.; BRITO-GITIRANA, L. de. Histopathologic analysis of \nhamster hepatocytes submitted to experimental infection with Leishmania donovani. \nParasitology Research, v. 88, n. 9, p. 829-836, 2002.  \n\nWADE, R. L. et al. Nephrotoxicity and other adverse events among inpatients receiving \nliposomal amphotericin B or amphotericin B lipid complex. Diagnostic Microbiology \nand Infectious Disease, v. 76, p. 361-367, 2013.  \n\nWALTERS, L. L. Leishmania differentiation in natural and unnatural sandfly hosts. \nJournal of Eukaryotic Microbiology, v. 40, n. 2, p. 196-206, 1993.  \n\nWALTERS, L. L. et al. Life cycle of Leishmania major (Kinetoplastida: \nTrypanosomatidae) in the neotropical sandfly Lutzomyia longipalpis (Diptera: \nPsychodidae). Journal of Medical Entomology, v. 30, n. 4, p. 699-718, 1993.  \n\n \n\n\n\n130 \n \n\nWASHINGTON, I. M.; VAN HOOSIER, G. The laboratory rabbit, guinea pig, hamster, \nand other rodents. London: Academic Press/Elsevier, 2012.  \n\nWHO. WORLD HEALTH ORGANIZATION. The leishmaniases. Geneva, 1984. (WHO \ntechinical reports series, 701).  \n\nWHO. WORLD HEALTH ORGANIZATION. Control of leishmaniases. Geneva, 2010. \n(WHO techinical reports series, 949).  \n\nWHO. WORLD HEALTH ORGANIZATION. Leishmaniasis: epidemiological situation of \nleishmaniasis. Dispon\u00edvel em:&lt;http://www.who.int/leishmaniasis/burden/en/>.                               \nAcesso em: 11 dez. 2016.  \n\nWHO. WORLD HEALTH ORGANIZATION. Neglected tropical disease. Dispon\u00edvel em: \n<http://www.who.int/neglected_diseases/diseases/en/>. Acesso em: 22 mar. 2017.  \n\nWILSON, S.; DUNNE, D. W. A pressing need for parasite immunologists to contribute to \nour understanding of human-neglected tropical diseases. Parasite Immunology, v. 36, \nn. 8, p. 325-327, 2014.  \n\nWINK, M. Medicinal plants: a source of anti-parasitic secondary metabolites. Molecules, \nv. 17, p. 12771-12791, 2012.  \n\nWORTMANN, G. et al. Lipsosomal amphotericin B for treatment of cutaneous \nleishmaniasis. The American Journal of Tropical Medicine and Hygiene, v. 83, n. 5, \np. 1028-1033, 2010.  \n\nXIONG, Z. H. et al. Selective transfer of calcium from an acidic compartment to the \nmitochondrion of Trypanosoma brucei. Measurements with targeted aequorins. Journal \nof Biological Chemistry, v. 272, n. 49, p. 31022-31028, 1997.  \n\nZIJLSTRA, E. E. PKDL and other dermal lesions in HIV co-infected patients with \nleishmaniasis: review of clinical presentation in relation to immune responses. PLoS \nNeglected Tropical Diseases, v. 8, n. 11, 2014. doi:10.1371/journal.pntd.0003258.  \n\nZOU, Z. et al. Synthesis and evaluation of furoxan-based nitric oxide-releasing \nderivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal \nagents. Bioorganic and Medicinal Chemistry Letters, v. 21, n. 19, p. 5934-5938, \n2011."}]}}}